[Phototoxic drugs and age-related maculopathy]

J Fr Ophtalmol. 2003 Jun;26(6):596-601.
[Article in French]

Abstract

Objectives: To disclose a correlation between age-related macular degeneration (AMD) and long-lasting treatments with potentially phototoxic drugs.

Design: Case-control study.

Methods: The case group was made up of 90 randomized patients, 65 years old or older, with documented AMD, examined in 1998 and 1999. The M/F sex ratio was 0.54, and mean age 79.9 years. The control group was randomized with age- and sex-matched subjects. In both groups, we noted long-lasting oral treatment for hypertension, diabetes mellitus, epilepsy, hyperuricemia, and psychiatric pathologies. All the study group patients underwent a complete ophthalmological examination for visual acuity, contrast sensitivity, biomicroscopy, fundus color and red-free photographs, fluorescein and ICG angiographies.

Results: When the study group was compared with the control group, neovascular AMD was positively associated with thiazide diuretics (p<0.001). When the study group was analyzed alone, intake of one or several antihypertensive drugs was positively associated with occult neovascularization and mild to moderate visual loss (p=0.009). Only thiazide diuretic intake was positively associated with severe bilateral loss of vision (p=0.041) and extensive choroidal neovascularization with major subretinal hemorrhages (p=0.022).

Conclusions: These findings suggest that severe neovascular AMD is associated with long-term thiazide diuretic treatment.

Publication types

  • Clinical Trial
  • English Abstract
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Aging
  • Benzothiadiazines*
  • Contrast Sensitivity
  • Diuretics
  • Female
  • Humans
  • Macular Degeneration / etiology*
  • Male
  • Photosensitizing Agents / adverse effects*
  • Reference Values
  • Sodium Chloride Symporter Inhibitors / adverse effects*
  • Vision Tests
  • Visual Acuity

Substances

  • Benzothiadiazines
  • Diuretics
  • Photosensitizing Agents
  • Sodium Chloride Symporter Inhibitors